A cost utility analysis of CYP2D6 pharmacogenetic guided dosing versus standard dosing of risperidone for treatment of schizophrenia

May 1, 2014, 00:00 AM
10.1016/j.jval.2014.03.1271
https://www.valueinhealthjournal.com/article/S1098-3015(14)01322-9/fulltext
Section Title : Mental Health
Section Order : 732
First Page : A217
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)01322-9&doi=10.1016/j.jval.2014.03.1271
HEOR Topics :
Tags :
Regions :